• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

MassDevice

The Medical Device Business Journal — Medical Device News & Articles | MassDevice

  • Latest News
  • Technologies
    • Artificial Intelligence (AI)
    • Cardiovascular
    • Orthopedics
    • Neurological
    • Diabetes
    • Surgical Robotics
  • Business & Finance
    • Wall Street Beat
    • Earnings Reports
    • Funding Roundup
    • Mergers & Acquisitions
    • Initial Public Offering (IPO)
    • Legal News
    • Personnel Moves
    • Medtech 100 Stock Index
  • Regulatory & Compliance
    • Food & Drug Administration (FDA)
    • Recalls
    • 510(k)
    • Pre-Market Approval (PMA)
    • MDSAP
    • Clinical Trials
  • Special Content
    • Special Reports
    • In-Depth Coverage
    • DeviceTalks
  • Podcasts
    • MassDevice Fast Five
    • DeviceTalks Weekly
    • OEM Talks
      • AbbottTalks
      • Boston ScientificTalks
      • DeviceTalks AI
      • IntuitiveTalks
      • MedtechWOMEN Talks
      • MedtronicTalks
      • Neuro Innovation Talks
      • Ortho Innovation Talks
      • Structural Heart Talks
      • StrykerTalks
  • Resources
    • About MassDevice
    • DeviceTalks
    • Newsletter Signup
    • Leadership in Medtech
    • Manufacturers & Suppliers Search
    • MedTech100 Index
    • Videos
    • Webinars
    • Whitepapers
    • Voices
Home » St. Jude Medical’s Allure Quadra pacemaker wins FDA OK

St. Jude Medical’s Allure Quadra pacemaker wins FDA OK

March 24, 2014 By Brad Perriello

St. Jude Medical's Allure Quadra pacemaker wins FDA OK

St. Jude Medical (NYSE:STJ) said its Allure Quadra pacemaker will be the 1st on the U.S. market to offer quadripolar cardiac resynchronization therapy after the FDA granted pre-market approval to the device.

The FDA also granted PMAs for St. Jude’s Assurity and Endurity pacemakers, St. Jude said. The St. Paul, Minn.-based medical device company also said it’s launching a new line of defibrillator leads based on its Durata platform but using its newer Optim insulation.

The Allure Quadra device provides more pacing configurations that standard bipolar pacing, according to a press release, meaning less risk of additional surgeries to adjust lead placement. The Allure line also features enhanced heart failure diagnostics, according to the release, and is equipped to ship data to St. Jude’s Merlin.net patient care network and to patients’ electronic health records. St. Jude said it plans to have the Allure Quadra on the U.S. market by the end of the month.

The Allure Quadra won CE Mark approval in the European Union a year ago.

"St. Jude Medical is the leader in quadripolar pacing technology, provided in our high voltage CRT-D devices since 2009. In International markets where the Allure Quadra CRT pacemaker is available, we experience strong demand and significant share capture as the technology has become the standard of care for many physicians," group president Dr.  Eric Fain said in prepared remarks. "Through product offerings like the Allure Quadra CRT-P and the Assurity and Endurity pacemakers, we continue to deliver innovation through a full continuum of pacemaker options."

"Adding the clinical benefits of quadripolar technology to pacemakers will expand the benefits of this therapy to patients. These features and additional pacing options will allow me to provide better care to patients diagnosed with heart failure and reduce the need for repeat procedures, especially for those patients who have been historically hard to treat due to tissue damage in their heart," added Dr. Raffaele Corbisiero of the Deborah Heart & Lung Center in Browns Mills, N.J. "This could have economic benefits as well due to fewer readmissions for heart failure-related events."

St. Jude also announced the global launch of its Optisure defibrillation lead, saying the device has regulatory nods in the U.S., European Union, Canada, Australia and Japan. The Optisure lead is based on St. Jude’s next-generation Durata platform, but uses additional Optim lead insulation. The newer design enhances the Optisure lead’s resistance to abrasion without sacrificing flexibility, according to a press release.

"Today’s announcement reinforces our commitment to continuous innovation across our entire cardiac rhythm management portfolio with a particular focus on system reliability," Fain said in a statement. "The Optisure lead builds on the proven track record of our Durata lead and Optim insulation, which is supported by a large body of evidence that will continue to grow through our active post-market registries."

Filed Under: Food & Drug Administration (FDA), News Well, Pre-Market Approval (PMA), Regulatory/Compliance Tagged With: Cardiac Rhythm Management, stjudemedical

More recent news

  • Ambu wins FDA clearance for first single-use cysto-nephroscope
  • Tandem Diabetes Care pairs t:slim X2 pump with Abbott FreeStyle Libre 3 Plus in U.S.
  • Ypsomed, CamDiab to integrate Abbott dual glucose-ketone sensor into automated insulin delivery system
  • Johnson & Johnson MedTech launches new Volt plating systems for radius, humerus
  • PharmaSens, SiBionics collab on all-in-one insulin patch pump

Primary Sidebar

“md
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest med device regulatory, business and technology news.

DeviceTalks Weekly

See More >

MEDTECH 100 Stock INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
MDO ad

Footer

MASSDEVICE MEDICAL NETWORK

DeviceTalks
Drug Delivery Business News
Medical Design & Outsourcing
Medical Tubing + Extrusion
Drug Discovery & Development
Pharmaceutical Processing World
MedTech 100 Index
R&D World
Medical Design Sourcing

DeviceTalks Webinars, Podcasts, & Discussions

Attend our Monthly Webinars
Listen to our Weekly Podcasts
Join our DeviceTalks Tuesdays Discussion

MASSDEVICE

Subscribe to MassDevice E-Newsletter
Advertise with us
About
Contact us

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy